Lipid nanoparticles deliver mRNA into cells. The engineering effort focuses on the nanoparticle: its lipid composition, surface charge, size, PEGylation. Better vehicles for the same cargo. CRISPR editing efficiency with optimized LNPs plateaus around 25% in a single dose.
Co-administering three amino acids — methionine, arginine, and serine — with unmodified LNPs increases mRNA expression 5-20x and lifts CRISPR editing efficiency from ~25% to ~90% in a single dose. The amino acids don't modify the nanoparticle or the mRNA. They modify the cell.
The through-claim: the receiver's mode of reception determines the signal's power more than the signal's construction. The amino acids switch the cell's endocytic pathway from clathrin-mediated to clathrin-independent carrier-mediated endocytosis — a fundamentally different uptake route. Clathrin-mediated endocytosis routes cargo through acidic lysosomes, which degrade most of the mRNA before it reaches the cytoplasm. The alternative pathway delivers cargo more efficiently, with less degradation.
The bottleneck was never the vehicle. It was which door the cell opened. Years of nanoparticle optimization were pushing against a ceiling set by the cell's uptake mechanism, not by the particle's design. Changing how the cell receives turned out to be more powerful than changing what it receives.
The practical consequence is striking: a simple amino acid supplement — cheap, generic, already in the body — outperforms years of sophisticated lipid engineering. The 20-fold improvement didn't require nanotechnology. It required understanding that delivery is a two-party interaction, and the receiving party's state matters at least as much as the sender's packaging.